Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
Financial Results:
- Neuland Laboratories Ltd. reported Total Income for Q4FY23 of ₹ 415.1 Crores up from ₹ 256.5 Crore year on year, a rise of 62%.
- Total Expenses for Q4FY23 of ₹ 305 Crores up from ₹ 232 Crores year on year, rise of 31%.
- Consolidated Net Profit of ₹ 84.5 Crores, up 287% from ₹ 21.8 Crores in the same quarter of the previous year.
- The Earnings per Share is ₹ 65.9, up 287% from ₹ 17 in the same quarter of the previous year.
